Review

Tapping the potential of quantum dots for personalized oncology: current status and future perspectives

Department of Oncology, Zhongnan Hospital of Wuhan University & Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, No 169 Donghu Road, Wuchang District, Wuhan 430071, PR China.

Department of Breast & Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, PR China

Search for more papers by this author

Jun Peng

Key Laboratory of Analytical Chemistry for Biology & Medicine (Ministry of Education), College of Chemistry & Molecular Sciences, Research Center for Nanobiology & Nanomedicine (MOE 985 Innovative Platform), & State Key Laboratory of Virology, Wuhan University, Wuhan, 430072, PR China

Wuhan Jiayuan Quantum Dots Co. Ltd & Wuhan Tumor Nanometer Diagnosis Engineering Research Center, Wuhan 430074, PR China

Search for more papers by this author

Sheng-Rong Sun

Department of Breast & Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, PR China

Search for more papers by this author

Chun-Wei Peng

Search for more papers by this author

Yan Li^‡

* Author for correspondence

^‡These authors contributed equally

Search for more papers by this author

Email the corresponding author at liyansd2@163.com

Dai-Wen Pang^‡

^‡These authors contributed equally

Search for more papers by this author

Published Online:2 Mar 2012https://doi.org/10.2217/nnm.12.9

View article

Abstract

Cancer is one of the most serious health threats worldwide. Personalized oncology holds potential for future cancer care in clinical practice, where each patient could be delivered individualized medicine on the basis of key biological features of an individual tumor. One of the most urgent problems is to develop novel approaches that incorporate the increasing molecular information into the understanding of cancer biological behaviors for personalized oncology. Quantum dots are a heterogeneous class of engineered fluorescent nanoparticles with unique optical and chemical properties, which make them promising platforms for biomedical applications. With the unique optical properties, the utilization of quantum dot-based nanotechnology has been expanded into a wide variety of attractive biomedical applications for cancer diagnosis, monitoring, pathogenesis, treatment, molecular pathology and heterogeneity in combination with cancer biomarkers. Here, we focus on the clinical application of quantum dot-based nanotechnology in personalized oncology, covering topics on individualized cancer diagnosis and treatment by in vitro and in vivo molecular imaging technologies, and in-depth understanding of the biological behaviors of tumors from a nanotechnology perspective. In addition, the major challenges in translating quantum dot-based nanotechnology into clinical application and promising future directions in personalized oncology are also discussed.

Keywords:

References

1 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin.61,69–90 (2011).
MedlineGoogle Scholar
2 Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW. Cancer screening in the United States, 2011: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J. Clin.61,8–30 (2011).
MedlineGoogle Scholar
3 Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J. Clin. Oncol.27,328–333 (2009).
MedlineGoogle Scholar
4 Cance WG. Society of surgical oncology presidential address: the war on cancer – shifting from disappointment to new hope. Ann. Surg. Oncol.17,1971–1978 (2010).
MedlineGoogle Scholar
5 Marshall E. Cancer research and the $90 billion metaphor. Science331,1540–1541 (2011).
Medline CASGoogle Scholar
6 Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin.60,277–300 (2010).
MedlineGoogle Scholar
7 Sankaranarayanan R, Swaminathan R, Brenner H et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol.11,165–173 (2010).
MedlineGoogle Scholar
8 Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta1805(1),105–117 (2010).
Medline CASGoogle Scholar
9 Hanash SM, Baik CS, Kallioniemi O. Emerging molecular biomarkers – blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol.8,142–150 (2011).
MedlineGoogle Scholar
10 Weissleder R. Molecular imaging in cancer. Science312,1168–1171 (2006).
Medline CASGoogle Scholar
11 Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature452,580–589 (2008).
Medline CASGoogle Scholar
12 van der Meel R, Gallagher WM, Oliveira S, O’Connor AE, Schiffelers RM, Byrne AT. Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies. Drug Discov. Today15,102–114 (2010).
Medline CASGoogle Scholar
13 Glunde K, Pathak AP, Bhujwalla ZM. Molecular-functional imaging of cancer: to image and imagine. Trends Mol. Med.13,287–297 (2007).
Medline CASGoogle Scholar
14 Harris TJ, McCormick F. The molecular pathology of cancer. Nat. Rev. Clin. Oncol.7,251–265 (2010).
Medline CASGoogle Scholar
15 Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer5,845–856 (2005).
Medline CASGoogle Scholar
16 Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin. Chem.54,1770–1779 (2008).
Medline CASGoogle Scholar
17 Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies. Nat. Rev. Clin. Oncol.8,135–141 (2011).
Medline CASGoogle Scholar
18 Phan JH, Moffitt RA, Stokes TH et al. Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. Trends Biotechnol.27,350–358 (2009).
Medline CASGoogle Scholar
19 Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin.58,97–110 (2008).
MedlineGoogle Scholar
20 Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol.2,751–760 (2007).
Medline CASGoogle Scholar
21 Torigian DA, Huang SS, Houseni M, Alavi A. Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J. Clin.57,206–224 (2007).
MedlineGoogle Scholar
22 Frangioni JV. New technologies for human cancer imaging. J. Clin. Oncol.26,4012–4021 (2008).
MedlineGoogle Scholar
23 Kim J, Piao Y, Hyeon T. Multifunctional nanostructured materials for multimodal imaging, and simultaneous imaging and therapy. Chem. Soc. Rev.38,372–390 (2009).
Medline CASGoogle Scholar
24 Hong H, Zhang Y, Sun J, Cai W. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today4,399–413 (2009).
Medline CASGoogle Scholar
25 Cho EC, Glaus C, Chen J, Welch MJ, Xia Y. Inorganic nanoparticle-based contrast agents for molecular imaging. Trends Mol. Med.16,561–573 (2010).
Medline CASGoogle Scholar
26 Farrell D, Alper J, Ptak K, Panaro NJ, Grodzinski P, Barker AD. Recent advances from the National Cancer Institute Alliance for nanotechnology in cancer. ACS Nano4,589–594 (2010).
Medline CASGoogle Scholar
27 Singhal S, Nie S, Wang MD. Nanotechnology applications in surgical oncology. Annu. Rev. Med.61,359–373 (2010).
Medline CASGoogle Scholar
28 Nie S, Xing Y, Kim GJ, Simons JW. Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng.9,257–288 (2007).
Medline CASGoogle Scholar
29 Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer5,161–171 (2005).
Medline CASGoogle Scholar
30 Michalet X, Pinaud FF, Bentolila LA et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science307,538–544 (2005).
Medline CASGoogle Scholar
31 Chen C, Chen LD, Zhang ZL, Li Y. Advances in the application of quantum dots in tumor markers investigation. Chin. Germ. J. Clin. Oncol.7,1079–1084 (2008).
Google Scholar
32 Peng CW, Li Y. Application of quantum dots-based biotechnology in cancer diagnosis: current status and future perspectives. J. Nanomater.676839,1–11 (2010).
Google Scholar
33 Zrazhevskiy P, Gao X. Multifunctional quantum dots for personalized medicine. Nano Today4,414–428 (2009).
Medline CASGoogle Scholar
34 Zrazhevskiy P, Sena M, Gao X. Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. Chem. Soc. Rev.39,4326–4354 (2010).
Medline CASGoogle Scholar
35 Smith AM, Dave S, Nie S, True L, Gao X. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev. Mol. Diagn.6(2),231–244 (2006).
Medline CASGoogle Scholar
36 Resch-Genger U, Grabolle, Cavaliere-Jaricot S, Nitschke R, Nann T. Quantum dots versus organic dyes as fluorescent labels. Nat. Methods5,763–775 (2008).
Medline CASGoogle Scholar
37 Tholouli E, Sweeney E, Barrow E, Clay V, Hoyland J, Byers R. Quantum dots light up pathology. J. Pathol.216,275–285 (2008).
Medline CASGoogle Scholar
38 Smith AM, Duan H, Mohs AM, Nie S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv. Drug Deliv. Rev.60,1226–1240 (2008).
Medline CASGoogle Scholar
39 Bentolila LA, Ebenstein Y, Weiss S. Quantum dots for in vivo small-animal imaging. J. Nucl. Med.50,493–496 (2009).
Medline CASGoogle Scholar
40 Kosaka N, McCann TE, Mitsunaga M, Choyke PL, Kobayashi H. Real-time optical imaging using quantum dot and related nanocrystals. Nanomedicine5,765–776 (2010).
CASGoogle Scholar
41 Hilderbrand SA, Weissleder R. Near-infrared fluorescence: application to in vivo molecular imaging. Curr. Opin. Chem. Biol.14,71–79 (2010).
Medline CASGoogle Scholar
42 He X, Gao J, Gambhir SS, Cheng Z. Near-infrared fluorescent nanoprobes for cancer molecular imaging: status and challenges. Trends Mol. Med.16,574–583 (2010).
MedlineGoogle Scholar
43 Wang Y, Chen L. Quantum dots, lighting up the research and development of nanomedicine. Nanomedicine7,385–402 (2011).
Medline CASGoogle Scholar
44 Byers RJ, Hitchman ER. Quantum dots brighten biological imaging. Prog. Histochem. Cytochem.45,201–237 (2011).
MedlineGoogle Scholar
45 Wagner MK, Li F, Li J, Li XF, Le XC. Use of quantum dots in the development of assays for cancer biomarkers. Anal. Bioanal. Chem.397,3213–3224 (2010).
Medline CASGoogle Scholar
46 Rosenthal SJ, Chang JC, Kovtun O, McBride JR, Tomlinson ID. Biocompatible quantum dots for biological applications. Chem. Biol.18,10–24 (2011).
Medline CASGoogle Scholar
47 Medintz IL, Mattoussi H, Clapp AR. Potential clinical applications of quantum dots. Int. J. Nanomedicine3,151–167 (2008).
Medline CASGoogle Scholar
48 Zhang H, Yee D, Wang C. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. Nanomedicine3,83–91 (2008).
CASGoogle Scholar
49 True LD, Gao X. Quantum dots for molecular pathology: their time has arrived. J. Mol. Diagn.9,7–11 (2007).
Medline CASGoogle Scholar
50 Jamieson T, Bakhshi R, Petrova D, Pocock R, Imani M, Seifalian AM. Biological applications of quantum dots. Biomaterials28,4717–4732 (2007).
Medline CASGoogle Scholar
51 Gao X, Yang L, Petros JA, Marshall FF, Simons JW, Nie S. In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol.16,63–72 (2005).
Medline CASGoogle Scholar
52 Algar WR, Krull UJ. Quantum dots as donors in fluorescence resonance energy transfer for the bioanalysis of nucleic acids, proteins, and other biological molecules. Anal. Bioanal. Chem.391,1609–1618 (2008).
Medline CASGoogle Scholar
53 Xia Z, Rao J. Biosensing and imaging based on bioluminescence resonance energy transfer. Curr. Opin. Biotechnol.20,37–44 (2009).
Medline CASGoogle Scholar
54 Bruchez M Jr, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science281,2013–2016 (1998).
Medline CASGoogle Scholar
55 Chan WC, Nie SM. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science281,2016–2018 (1998).
Medline CASGoogle Scholar
56 Mankoff DA. A definition of molecular imaging. J. Nucl. Med.48,18N–21N (2007).
MedlineGoogle Scholar
57 Yang L, Mao H, Wang YA et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. Small5,235–243 (2009).
Medline CASGoogle Scholar
58 Yong KT, Ding H, Roy I et al. Imaging pancreatic cancer using bioconjugated InP quantum dots. ACS Nano3,502–510 (2009).
Medline CASGoogle Scholar
59 Diagaradjane P, Orenstein-Cardona JM, Colon-Casasnovas NE et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin. Cancer Res.14,731–741 (2008).▪ Comprehensive in vivo evaluation of the distribution and metabolism of bioconjugated quantum dot (QD) probes.
Medline CASGoogle Scholar
60 Biju V, Itoh T, Ishikawa M. Delivering quantum dots to cells: bioconjugated quantum dots for targeted and nonspecific extracellular and intracellular imaging. Chem. Soc. Rev.39,3031–3056 (2010).
Medline CASGoogle Scholar
61 Wang C, Gao X, Su X. In vitro and in vivo imaging with quantum dots. Anal. Bioanal. Chem.397,1397–1415 (2010).
Medline CASGoogle Scholar
62 Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc. Natl Acad. Sci. USA99,12617–12621 (2002).
Medline CASGoogle Scholar
63 Gao XH, Cui YY, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol.22,969–976 (2004).▪▪ The first work using QD bioprobes for in vivo imaging.
Medline CASGoogle Scholar
64 Gao XH, Chung LW, Nie SM. Quantum dots for in vivo molecular and cellular imaging. Methods Mol. Biol.374,135–146 (2007).
Medline CASGoogle Scholar
65 Cai W, Shin DW, Chen K et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett.6,669–676 (2006).
Medline CASGoogle Scholar
66 Cai W, Chen K, Li ZB, Gambhir SS, Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J. Nucl. Med.48,1862–1870 (2007).
Medline CASGoogle Scholar
67 Yu X, Chen L, Li K et al. Immunofluorescence detection with quantum dot bioconjugates for hepatoma in vivo. J. Biomed. Opt.12,014008 (2007).
MedlineGoogle Scholar
68 Yu X, Chen L, Deng Y et al. Fluorescence analysis with quantum dot probes for hepatoma under one- and two-photon excitation. J. Fluoresc.17,243–247 (2007).
Medline CASGoogle Scholar
69 Chen LD, Liu J, Yu XF et al.In vivo targeted imaging of hepatocellular carcinoma in nude mice using quantum dot probes. Chin. J. Pathol.36,394–399 (2007).
CASGoogle Scholar
70 Chen LD, Liu J, Yu XF et al. The biocompatibility of quantum dot probes used for the targeted imaging of hepatocellular carcinoma metastasis. Biomaterials29,4170–4176 (2008).
Medline CASGoogle Scholar
71 Kim S, Lim YT, Soltesz EG et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol.22,93–97 (2004).
Medline CASGoogle Scholar
72 Hama Y, Koyama Y, Urano Y, Choyke PL, Kobayashi H. Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity. Breast Cancer Res. Treat.103,23–28 (2007).
MedlineGoogle Scholar
73 Kobayashi H, Hama Y, Koyama Y et al. Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett.7,1711–1716 (2007).
Medline CASGoogle Scholar
74 Kosaka N, Ogawa M, Sato N, Choyke PL, Kobayashi H. In vivo real-time, multicolor, quantum dot lymphatic imaging. J. Invest. Dermatol.129,2818–2822 (2009).
Medline CASGoogle Scholar
75 Pons T, Pic E, Lequeux N et al. Cadmium-free CuInS2/ZnS quantum dots for sentinel lymph node imaging with reduced toxicity. ACS Nano4,2531–2538 (2010).
Medline CASGoogle Scholar
76 Erogbogbo F, Yong KT, Roy I et al.In vivo targeted cancer imaging, sentinel lymph node mapping and multi-channel imaging with biocompatible silicon nanocrystals. ACS Nano5,413–423 (2011).
Medline CASGoogle Scholar
77 Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science331,1559–1564 (2011).
Medline CASGoogle Scholar
78 Voura EB, Jaiswal JK, Mattoussi H, Simon SM. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat. Med.10,993–998 (2004).
Medline CASGoogle Scholar
79 Lidke DS, Nagy P, Heintzmann R et al. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat. Biotechnol.22,198–203 (2004).
Medline CASGoogle Scholar
80 Gonda K, Watanabe TM, Ohuchi N, Higuchi H. In vivo nano-imaging of membrane dynamics in metastatic tumor cells using quantum dots. J. Biol. Chem.285,2750–2757 (2010).▪ The first work using QD imaging of the cell membrane dynamics during cancer metatasis.
Medline CASGoogle Scholar
81 Misra RD. Quantum dots for tumor-targeted drug delivery and cell imaging. Nanomedicine3,271–274 (2008).
CASGoogle Scholar
82 Tada H, Higuchi H, Wanatabe TM, Ohuchi N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res.67,1138–1144 (2007).
Medline CASGoogle Scholar
83 Nurunnabi M, Cho KJ, Choi JS, Huh KM, Lee YK. Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. Biomaterials31,5436–5444 (2010).
Medline CASGoogle Scholar
84 Bagalkot V, Zhang L, Levy-Nissenbaum E et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett.7,3065–3070 (2007).
Medline CASGoogle Scholar
85 Weng KC, Noble CO, Papahadjopoulos-Sternberg B et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett.8,2851–2857 (2008).
Medline CASGoogle Scholar
86 Pan J, Liu Y, Feng SS. Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment. Nanomedicine5,347–360 (2010).
CASGoogle Scholar
87 Lu RM, Chang YL, Chen MS, Wu HC. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials32,3265–3274 (2011).
Medline CASGoogle Scholar
88 Ashley CE, Carnes EC, Phillips GK et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat. Mater.10,389–397 (2011).
Medline CASGoogle Scholar
89 Muhammad F, Guo M, Qi W et al. pH-triggered controlled drug release from mesoporous silica nanoparticles via intracelluar dissolution of ZnO nanolids. J. Am. Chem. Soc.133,8778–8781 (2011).
Medline CASGoogle Scholar
90 Petrocca F, Lieberman J. Promise and challenge of RNA interference-based therapy for cancer. J. Clin. Oncol.29,747–754 (2011).
Medline CASGoogle Scholar
91 Agrawal P, Strijkers GJ, Nicolay K. Chitosan-based systems for molecular imaging. Adv. Drug Deliv. Rev.62,42–58 (2010).
Medline CASGoogle Scholar
92 Tan WB, Jiang S, Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials28,1565–1571 (2007).
Medline CASGoogle Scholar
93 Chen HH, Ho YP, Jiang X, Mao HQ, Wang TH, Leong KW. Quantitative comparison of intracellular unpacking kinetics of polyplexes by a model constructed from quantum dot-FRET. Mol. Ther.16,324–332 (2008).
Medline CASGoogle Scholar
94 Yezhelyev MV, Qi L, O’Regan RM, Nie S, Gao X. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J. Am. Chem. Soc.130,9006–9012 (2008).
Medline CASGoogle Scholar
95 Juzenas P, Chen W, Sun YP et al. Quantum dots and nanoparticles for photodynamic and radiation therapies of cancer. Adv. Drug Deliv. Rev.60,1600–1614 (2008).
Medline CASGoogle Scholar
96 Yaghini E, Seifalian AM, MacRobert AJ. Quantum dots and their potential biomedical applications in photosensitization for photodynamic therapy. Nanomedicine4,353–363 (2009).
CASGoogle Scholar
97 Biju V, Mundayoor S, Omkumar RV, Anas A, Ishikawa M. Bioconjugated quantum dots for cancer research: present status, prospects and remaining issues. Biotechnol. Adv.28,199–213 (2010).
Medline CASGoogle Scholar
98 Triesscheijin M, Baas P, Schellens JH, Stewart FA. Photodynamic therapy in oncology. Oncologist11,1034–1044 (2006).
MedlineGoogle Scholar
99 Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist14,320–368 (2009).
Medline CASGoogle Scholar
100 Wu X, Liu H, Liu J et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat. Biotechnol.21,41–46 (2003).
Medline CASGoogle Scholar
101 Yezhelyev MV, Al-Hajj A, Morris C et al.In situ molecular profiling of breast cancer biomarkers with multicolor quantum dots. Adv. Mater.19,3146–3151 (2007).▪ The first work using QD imaging of multiple biomarkers in breast cancer tissue.
CASGoogle Scholar
102 Chen C, Peng J, Xia HS et al. Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials30,2912–2918 (2009).
Medline CASGoogle Scholar
103 Chen C, Peng J, Xia HS et al. Quantum-dot-based immunofluorescent imaging of HER2 and ER provides new insights into breast cancer heterogeneity. Nanotechnology21,95101 (2010).
Google Scholar
104 Chen C, Xia HS, Gong YP et al. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis. Biomaterials31,8818–8825 (2010).
Medline CASGoogle Scholar
105 Chen C, Sun SR, Gong YP et al. Quantum dots-based molecular classification of breast cancer by quantitative spectroanalysis of hormone receptors and HER2. Biomaterials32,7592–7599 (2011).▪▪ QD imaging of key cancer biomarkers in complex tissue microarray breast cancer specimens with quantitative spectroanalysis to develop a new algorithm of breast cancer classification.
Medline CASGoogle Scholar
106 Li R, Dai H, Wheeler TM et al. Prognostic value of Akt-1 in human prostate cancer: a computerized quantitative assessment with quantum dot technology. Clin. Cancer Res.15,3568–3573 (2009).
Medline CASGoogle Scholar
107 Ghazani AA, Lee JA, Klostranec J et al. High throughput quantification of protein expression of cancer antigens in tissue microarray using quantum dot nanocrystals. Nano Lett.6,2881–2886 (2006).
Medline CASGoogle Scholar
108 Xing Y, Chaudry Q, Shen C et al. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat. Protoc.2,1152–1165 (2007).
Medline CASGoogle Scholar
109 Sweeney E, Ward TH, Gray N et al. Quantitative multiplexed quantum dot immunohistochemistry. Biochem. Biophys. Res. Commun.374,181–186 (2008).
Medline CASGoogle Scholar
110 Huang D, Peng X, Su L et al. Comparison and optimization of multiplexed quantum dot-based immunohistofluorescence. Nano Res.3,61–68 (2010).
CASGoogle Scholar
111 Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M. Identification of CD44v6⁺/CD24^- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest.89,857–866 (2009).
Medline CASGoogle Scholar
112 Liu J, Lau SK, Varma VA, Kairdolf BA, Nie S. Multiplexed detection and characterization of rare tumor cells in Hodgkin’s lymphoma with multicolor quantum dots. Anal. Chem.82,6237–6243 (2010).▪▪ Multicolor imaging to simultaneously identify major cellular components in complex cancer tissue.
Medline CASGoogle Scholar
113 Frasco MF, Chaniotakis N. Bioconjugated quantum dots as fluorescent probes for bioanalytical applications. Anal. Bioanal. Chem.396,229–240 (2010).
Medline CASGoogle Scholar
114 Gill R, Zayats M, Willner I. Semiconductor quantum dots for bioanalysis. Angew. Chem. Int. Ed. Engl.47,7602–7625 (2008).
Medline CASGoogle Scholar
115 Sun B, Xie W, Yi G, Chen D, Zhou Y, Cheng J. Microminiaturized immunoassays using quantum dots as fluorescent label by laser confocal scanning fluorescence detection. J. Immunol. Methods249,85–89 (2001).
Medline CASGoogle Scholar
116 Agrawal A, Sathe T, Nie S. Single-bead immunoassays using magnetic microparticles and spectral-shifting quantum dots. J. Agric. Food Chem.55,3778–3782 (2007).
Medline CASGoogle Scholar
117 Zajac A, Song D, Qian W, Zhukov T. Protein microarrays and quantum dot probes for early cancer detection. Colloids Surf. B Biointerfaces58,309–314 (2007).
Medline CASGoogle Scholar
118 Kerman K, Endo T, Tsukamoto M, Chikae M, Takamura Y, Tamiya E. Quantum dot-based immunosensor for the detection of prostate-specific antigen using fluorescence microscopy. Talanta71,1494–1499 (2007).
Medline CASGoogle Scholar
119 Wang J, Liu G, Wu H, Lin Y. Quantum-dot-based electrochemical immunoassay for high-throughput screening of the prostate-specific antigen. Small4,82–86 (2008).
Medline CASGoogle Scholar
120 Cui D, Pan B, Zhang H et al. Self-assembly of quantum dots and carbon nanotubes for ultrasensitive DNA and antigen detection. Anal. Chem.80,7996–8001 (2008).
Medline CASGoogle Scholar
121 Gokarna A, Jin LH, Hwang JS et al. Quantum dot-based protein micro- and nanoarrays for detection of prostate cancer biomarkers. Proteomics8,1809–1818 (2008).
Medline CASGoogle Scholar
122 Kim YP, Oh YH, Oh E, Ko S, Han MK, Kim HS. Energy transfer-based multiplexed assay of proteases by using gold nanoparticle and quantum dot conjugates on a surface. Anal. Chem.80,4634–4641 (2008).
Medline CASGoogle Scholar
123 Xia Z, Xing Y, So MK, Koh AL, Sinclair R, Rao J. Multiplex detection of protease activity with quantum dot nanosensors prepared by intein-mediated specific bioconjugation. Anal. Chem.80,8649–8655 (2008).
Medline CASGoogle Scholar
124 Zhang B, Liang X, Hao L et al. Quantum dots/particle-based immunofluorescence assay: synthesis, characterization and application. J. Photochem. Photobiol. B94,45–50 (2009).
Medline CASGoogle Scholar
125 Soman C, Giorgio T. Sensitive and multiplexed detection of proteomic antigens via quantum dot aggregation. Nanomedicine5,402–409 (2009).
Medline CASGoogle Scholar
126 Cheng AK, Su H, Wang YA, Yu HZ. Aptamer-based detection of epithelial tumor marker mucin 1 with quantum dot-based fluorescence readout. Anal. Chem.81,6130–6139 (2009).
Medline CASGoogle Scholar
127 Boeneman K, Mei BC, Dennis AM et al. Sensing caspase-3 activity with quantum dot-fluorescent protein assemblies. J. Am. Chem. Soc.131,3828–3829 (2009).
Medline CASGoogle Scholar
128 Jokerst JV, Raamanathan A, Christodoulides N et al. Nano-bio-chips for high performance multiplexed protein detection: determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. Biosens. Bioelectron.24,3622–3629 (2009).
Medline CASGoogle Scholar
129 Hu M, Yan J, He Y et al. Ultrasensitive, multiplexed detection of cancer biomarkers directly in serum by using a quantum dot-based microfluidic protein chip. ACS Nano4,488–494 (2010).
Medline CASGoogle Scholar
130 Cheng W, Yan F, Ding L, Ju H, Yin Y. Cascade signal amplification strategy for subattomolar protein detection by rolling circle amplification and quantum dots tagging. Anal. Chem.82,3337–3342 (2010).
Medline CASGoogle Scholar
131 Gu B, Xu C, Yang C, Liu S, Wang M. ZnO quantum dot labeled immunosensor for carbohydrate antigen 19–19. Biosens. Bioelectron.26,2720–2723 (2011).
Medline CASGoogle Scholar
132 Nelson NJ. Circulating tumor cells: will they be clinically useful? J. Natl Cancer Inst.102,146–148 (2010).
MedlineGoogle Scholar
133 Wang DS, He JB, Rosenzweig N, Rosenzweig Z. Superparamagnetic Fe₂O₃ Beads-CdSe/ZnS quantum dots core-shell nanocomposite particles for cell separation. Nano Lett.4,409–413 (2004).
CASGoogle Scholar
134 Selvan ST, Patra PK, Ang CY, Ying JY. Synthesis of silica-coated semiconductor and magnetic quantum dots and their use in the imaging of live cells. Angew. Chem. Int. Ed. Engl.46,2448–2452 (2007).
Medline CASGoogle Scholar
135 Di Corato R, Bigall NC, Ragusa A et al. Multifunctional nanobeads based on quantum dots and magnetic nanoparticles: synthesis and cancer cell targeting and sorting. ACS Nano5,1109–1121 (2011).
Medline CASGoogle Scholar
136 Hsieh YH, Lai LJ, Liu SJ, Liang KS. Rapid and sensitive detection of cancer cells by coupling with quantum dots and immunomagnetic separation at low concentrations. Biosens. Bioelectron.26,4249–4252 (2011).
Medline CASGoogle Scholar
137 Xie HY, Zuo C, Liu Y et al. Cell-targeting multifunctional nanospheres with both fluorescence and magnetism. Small1,506–509 (2005).
Medline CASGoogle Scholar
138 Xie HY, Xie M, Zhang ZL et al. Wheat germ agglutinin-modified trifunctional nanospheres for cell recognition. Bioconjug. Chem.18,1749–1755 (2007).
Medline CASGoogle Scholar
139 Song EQ, Wang GP, Xie HY et al. Visual recognition and efficient isolation of apoptotic cells with fluorescent-magnetic-biotargeting multifunctional nanospheres. Clin. Chem.53,2177–2185 (2007).
Medline CASGoogle Scholar
140 Song EQ, Hu J, Wen CY et al. Fluorescent-magnetic-biotargeting multifunctional nanobioprobes for detecting and isolating multiple types of tumor cells. ACS Nano5,761–770 (2011).
Medline CASGoogle Scholar
141 Stroh M, Zimmer JP, Duda DG et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med.11,678–682 (2005).
Medline CASGoogle Scholar
142 Estrada CR, Salanga M, Bielenberg DR et al. Behavioral profiling of human transitional cell carcinoma ex vivo. Cancer Res.66,3078–3086 (2006).
Medline CASGoogle Scholar
143 Chung GG, Zerkowski MP, Ghosh S, Camp RL, Rimm DL. Quantitative analysis of estrogen receptor heterogeneity in breast cancer. Lab Invest.87,662–669 (2007).
Medline CASGoogle Scholar
144 Liu J, Lau SK, Varma VA et al. Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots. ACS Nano4,2755–2765 (2010).
Medline CASGoogle Scholar
145 Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat. Rev. Cancer9,239–252 (2009).
Medline CASGoogle Scholar
146 Peng CW, Liu XL, Liu X, Li Y. Co-evolution of cancer microenvironment reveals distinctive patterns of gastric cancer invasion: laboratory evidence and clinical significance. J. Transl. Med.8,101 (2010).
MedlineGoogle Scholar
147 Peng CW, Liu XL, Chen C et al. Patterns of cancer invasion revealed by QDs-based quantitative multiplexed imaging of tumor microenvironment. Biomaterials32,2907–2917 (2011).▪▪ Simultaneous in situ imaging of cellular and molecular ingredients of the cancer microenvironment to reveal patterns of cancer invasion.
Medline CASGoogle Scholar
148 Liu XL, Peng CW, Chen C et al. Quantum dots-based double-color imaging of HER2 positive breast cancer invasion. Biochem. Biophys. Res. Commun.409,577–582 (2011).
Medline CASGoogle Scholar
149 Dubertret B, Skourides P, Norris DJ, Noireaux V, Brivanlou AH, Libchaber A. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science298,1759–1762 (2002).
Medline CASGoogle Scholar
150 Jaiswal J K, Mattoussi H, Mauro JM, Simon SM. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat. Biotechnol.21,47–51 (2003).
Medline CASGoogle Scholar
151 Hardman R. A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ. Health Perspect.114,165–172 (2006).
MedlineGoogle Scholar
152 Choi AO, Brown SE, Szyf M, Maysinger D. Quantum dot-induced epigenetic and genotoxic changes in human breast cancer cells. J. Mol. Med.86,291–302 (2008).
Medline CASGoogle Scholar
153 Fitzpatrick JA, Andreko SK, Ernst LA, Waggoner AS, Ballou B, Bruchez MP. Long-term persistence and spectral blue shifting of quantum dots in vivo. Nano Lett.9,2736–2741 (2009).
Medline CASGoogle Scholar
154 Zhang LW, Monteiro-Riviere NA. Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol. Sci.110,138–155 (2009).
Medline CASGoogle Scholar
155 Yong KT, Roy I, Ding H, Bergey EJ, Prasad PN. Biocompatible near-infrared quantum dots as ultrasensitive probes for long-term in vivo imaging applications. Small5,1997–2004 (2009).
Medline CASGoogle Scholar
156 Chu M, Wu Q, Yang H et al. Transfer of quantum dots from pregnant mice to pups across the placental barrier. Small6,670–678 (2010).
Medline CASGoogle Scholar
157 Pelley JL, Daar AS, Saner MA. State of academic knowledge on toxicity and biological fate of quantum dots. Toxicol. Sci.112,276–296 (2009).
Medline CASGoogle Scholar
158 Su Y, Peng F, Jiang Z et al.In vivo distribution, pharmacokinetics, and toxicity of aqueous synthesized cadmium-containing quantum dots. Biomaterials32,5855–5862 (2011).
Medline CASGoogle Scholar
159 Yang RS, Chang LW, Wu JP et al. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ. Health Perspect.115,1339–1343 (2007).
Medline CASGoogle Scholar
160 Choi HS, Liu W, Misra P et al. Renal clearance of quantum dots. Nat. Biotechnol.25,1165–1170 (2007).
Medline CASGoogle Scholar
161 Choi HS, Liu W, Liu F et al. Design considerations for tumour-targeted nanoparticles. Nat. Nanotechnol.5,42–47 (2010).
Medline CASGoogle Scholar
162 Choi HS, Ipe BI, Misra P, Lee JH, Bawendi MG, Frangioni JV. Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett.9,2354–2359 (2009).
Medline CASGoogle Scholar
163 Su Y, Hu M, Fan C et al. The cytotoxicity of CdTe quantum dots and the relative contributions from released cadmium ions and nanoparticle properties. Biomaterials31,4829–4834 (2010).
Medline CASGoogle Scholar
164 Barua S, Rege K. Cancer-cell-phenotype-dependent differential intracellular trafficking of unconjugated quantum dots. Small5,370–376 (2009).
Medline CASGoogle Scholar
165 Williams Y, Sukhanova A, Nowostawska M et al. Probing cell-type-specific intracellular nanoscale barriers using size-tuned quantum dots. Small5,2581–2588 (2009).
Medline CASGoogle Scholar
166 Geys J, Nemmar A, Verbeken E et al. Acute toxicity and prothrombotic effects of quantum dots: impact of surface charge. Environ. Health Perspect.116,1607–1613 (2008).
Medline CASGoogle Scholar
167 Clift MJ, Brandenberger C, Rothen-Rutishauser B, Brown DM, Stone V. The uptake and intracellular fate of a series of different surface coated quantum dots in vitro. Toxicology286,58–68 (2011).
Medline CASGoogle Scholar
168 Hauck TS, Anderson RE, Fischer HC, Newbigging S, Chan WC. In vivo quantum-dot toxicity assessment. Small6,138–144 (2010).
Medline CASGoogle Scholar
169 Selvan ST, Patra PK, Ang CY, Ying JY. Synthesis of silica-coated semiconductor and magnetic quantum dots and their use in the imaging of live cells. Angew. Chem. Int. Ed. Engl.46,2448–2452 (2007).
Medline CASGoogle Scholar
170 Erogbogbo F, Yong KT, Roy I, Xu G, Prasad PN, Swihart MT. Biocompatible luminescent silicon quantum dots for imaging of cancer cells. ACS Nano2,873–878 (2008).
Medline CASGoogle Scholar
171 Hu X, Gao X. Silica-polymer dual layer-encapsulated quantum dots with remarkable stability. ACS Nano4,6080–6086 (2010).
Medline CASGoogle Scholar
172 Erogbogbo F, Tien CA, Chang CW et al. Bioconjugation of luminescent silicon quantum dots for selective uptake by cancer cells. Bioconjug. Chem.22,1081–1088 (2011).
Medline CASGoogle Scholar
173 Bottrill M, Green M. Some aspects of quantum dot toxicity. Chem. Commun.47,7039–7050 (2011).
Medline CASGoogle Scholar
174 Xu H, Chen C, Peng J et al. Evaluation of bioconjugate efficiency of different quantum dots probes immunostaining tumor marker protein. Appl. Spectrosc.64,847–852 (2010).
Medline CASGoogle Scholar
175 Yang XQ, Chen C, Peng CW et al. Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal factor receptor in breast cancer tissue arrays. Int. J. Nanomed.6,2265–2273 (2011).
Medline CASGoogle Scholar

Vol. 7, No. 3

Metrics

Downloaded 438 times

History

Published online 2 March 2012

Published in print March 2012

Information

Keywords

Financial & competing interests disclosure

This research was supported by the Scholarship Award for Excellent Doctoral Student granted by Ministry of Education (2010), the National Natural Science Foundation of China (No 81171396) and for Creative Research Groups (No 20621502 and 20921062), the National Key Scientific Program (973)-Nanoscience and Nanotechnology (No 2006CB933100 and 2011CB933600), the National Science Foundation for Distinguished Young Scholars of China (No 81000974), and the Fundamental Research Funds for the Central Universities of Ministry of Education of China (No 4103005). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download